Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, Viatris License Agreement (Details)

v3.24.2.u1
License and Collaboration Agreements, Viatris License Agreement (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Jun. 30, 2024
USD ($)
Performanceobligation
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Performanceobligation
Jun. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Collaboration and License Agreement [Abstract]              
Revenue recognized     $ 1,112 $ 3,674 $ 2,823 $ 5,423  
Reconciliation of Closing Balance of Contract Asset [Abstract]              
Revenue recognized     $ 1,112 3,674 $ 2,823 5,423  
Viatris License Agreement [Member]              
Collaboration and License Agreement [Abstract]              
Non-refundable cash payment received   $ 35,000          
Maximum amount of payments receivable for development, regulatory and commercial milestones $ 130,000            
Milestone payments to be received 10,000            
Maximum percentage of tiered royalties receivable     20.00%   20.00%    
Number of distinct performance obligations | Performanceobligation     2   2    
Aggregate transaction price to be recognized         $ 40,000    
Period of non-cancellation window agreement         120 days    
Non-cancellation period of constrained         120 days    
Royalty payments     $ 19,000   $ 22    
Revenue recognized     1,100 3,700 2,823 5,423  
Reconciliation of Closing Balance of Contract Asset [Abstract]              
Beginning Balance         1,407 3,552  
Revenue recognized     1,100 3,700 2,823 5,423  
Ending Balance     $ 948 $ 2,595 948 2,595  
Viatris License Agreement [Member] | License Transfer Fee [Member]              
Collaboration and License Agreement [Abstract]              
Aggregate transaction price to be recognized         35,000    
Estimated standalone selling price for license agreement 287,800            
Transaction price allocation of ESSP obligations 39,300            
Reconciliation of Closing Balance of Contract Asset [Abstract]              
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement         (3,282) $ (6,380)  
Viatris License Agreement [Member] | Research and Development Services [Member]              
Collaboration and License Agreement [Abstract]              
Aggregate transaction price to be recognized         5,000    
Estimated standalone selling price for license agreement 5,000            
Transaction price allocation of ESSP obligations $ 700            
Viatris License Agreement [Member] | Sales Milestones [Member]              
Collaboration and License Agreement [Abstract]              
Milestone payment requirements attributed to the FDA's approval             $ 10,000
Revenue recognized         0    
Reconciliation of Closing Balance of Contract Asset [Abstract]              
Revenue recognized         $ 0